Tauriga Sciences, Inc. Completes Manufacturing of CannaCaviar CBD Soft Gels
LOS ANGELES, CALIFORNIA — (Monday. February 23, 2015 ) – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced today that it has manufactured its CannaCaviar line of cannabidiol (CBD) soft gels, which will be available for sale later this week. CannaCaviar is Tauriga’s second product that utilizes cannabidiol (CBD) oil extracted from non-GMO industrial hemp as its key ingredient. The Company also sells TopiCanna, a proprietary topical medicinal cannabis cream. Many who have used topical cannabis creams have reported decreased musculoskeletal pain. Both TopiCanna and CannaCaviar are designed to provide potential natural wellness and healing properties without psychoactive effects.
Cannabidiol (CBD), like THC (tetrahydrocannabinol), is one of the key compounds in cannabis. CBD and THC are two of the best known and most prevalent of over 60 compounds in a class of molecules known of cannabinoids. CBD has been associated with many medicinal properties and therapeutic benefits, yet unlike THC, it does not create a psychoactive “high.” Preclinical studies using animal models suggest that CBD has anticonvulsant, anxiolytic/anti-depressant, anti-inflammatory, antiemetic, and anti-oxidant properties. As such, CBD may have important therapeutic benefits in the treatment of a wide range of conditions, including chronic pain, neurodegenerative diseases, anxiety, nausea, cancer, arthritis, and other health concerns.
CBD can be derived either from medical marijuana plants or from industrially grown hemp plants. Both are varieties of cannabis. However, the legal and regulatory status of CBD oil extracted from industrial hemp is different from that of CBD oil extracted from medical marijuana plants, in large part because medical marijuana plants contain varying amounts of the psychoactive compound THC, while industrial hemp contains virtually no THC. The United States Food and Drug Administration (FDA) classifies hemp oil (and its derivative CBD) to be a dietary supplement and not a medication. Accordingly, Tauriga’s CannaCaviar and other products that use CBD oil from industrial hemp can be purchased and consumed legally in any state without a prescription.
Tauriga’s Chairman & CEO Dr. Stella Sung stated, “We are extremely pleased to add a second CBD-based product to our natural wellness product line. We believe that the success of medical marijuana will depend on the introduction of innovative products that could serve as natural alternatives to conventional therapies without harmful side effects. Moreover, Tauriga is now at a stage where we are beginning to generate and grow a revenue stream.”
In addition to CannaCaviar and TopiCanna, Tauriga has recently launched a non-cannabis containing line of natural wellness dietary supplements. These natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and MendWCan, a highly pure, potent and palatable Omega 3 supplement. For more information on Tauriga’s natural wellness product line, please visit www.taurigastore.com.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com and the Company’s e-commerce website at www.taurigastore.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697